Phase 3 N=167 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Number of Participants Monitored for Long-Term Safety of Valbenazine — 45; 107; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=154 Genetic Determinants of Response to Beta Blockade
Healthy
Primary: Reduction in Heart Rate — 7.9; 6; 3.3; 9.6 beats per minute
Phase 3 N=377 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
HIV Infections
Primary: Time to Failure of First Line Therapy or Death — 48; 32; 26 Participants — p=0.02
Phase 4 N=620 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
Immunity to Oral Rotavirus Vaccine · Immunity to Oral Polio Vaccine · Shedding of Oral Rotavirus Vaccine
Primary: Number/Percentage of Subjects With Immune Response to Rotavirus Vaccine — 54; 40; 42; 37 Participants
Phase 1 N=13 Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Number of Subjects Reporting Adverse Events — 13 Participants
Phase 2 N=33 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy
Diabetic Retinopathy
Primary: The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group — 2.80; 0.13 dB
Phase 1 N=120 Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Primary: Comparison of Areas Under the Curve (AUC) to the Last Time With a Concentration ≥ LLOQ [AUC0-t] and to Infinity [AUCinf] — 2,313; 2,098; 2,469; 2,175 hr x ng/mL
Phase 2 N=202 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
Patent Ductus Arteriosus · Surgery · Necrotizing Enterocolitis
Primary: Number of Infants Who Undergo in Hospital PDA Ligations or Who Have an Open Ductus at the Time of Discharge (That Need Future Outpatient Cardiology Follow-up Visits)…
Phase 3 N=735 Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Number of Participants With Early Clinical Response — 315; 297; 26; 32 Participants
Phase 2 N=28 Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Stage IV Pancreatic Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=32 Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Atherosclerosis · Cardiovascular Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 3; 3; 3; 4 Participants
Phase 1 N=2 The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)
Healthy
Primary: Peak Plasma 2-AAA Concentration Percentage Change From Baseline — 63.4 Percentage Change
N/A N=84 Defining Remission With Etanercept in AS in Real Life Clinical Practice
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved Assessment of SpondyloArthritis International Society (ASAS) Partial Remission at Month 6 and Maintained Till Month 12 — 14.7…
N/A N=33 Clinical Evaluation of the OEC Elite MD for Vascular Procedures at Hamilton General Hospital
Interventional Vascular Conditions
Primary: Image Guidance Adequacy Collected Via Survey Questionnaire — 30 Participants
N/A N=454 Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening
Colorectal Cancer
Primary: Completion of Colorectal Cancer Screening Tests — 102; 142; 88; 122 Participants — p=.005